COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cabozantinib and Nivolumab for Carcinoid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04197310
Recruitment Status : Recruiting
First Posted : December 13, 2019
Last Update Posted : January 6, 2020
Bristol-Myers Squibb
Information provided by (Responsible Party):
Kimberly Perez, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 26, 2021
Estimated Study Completion Date : December 26, 2022